Hantavirus vaccine in 2026?

As of Sun, 22 Nov 2026 17:34:28 UTC, Polymarket traders price Yes (1.8%). The market has $156K in volume and closes on Fri, 01 Jan 2027.

Updated:

Current odds

OutcomeChanceYes priceNo price
Yes1.8%1.8¢98.2¢

Market details

Resolution rules

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.

Sources

Related markets

More markets like this

A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use

DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.